Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Investigational HSV-2 Vaccines in Adults With Recurrent Genital Herpes
NCT04222985Phase 1Terminated
- Sponsor
- Sanofi
- Start
- Feb 2020
- Primary completion
- May 2021
- Modality
- Oncolytic Viruses, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HSV-529 and G103 in genital herpes (7 arms), sponsored by Sanofi. Primary endpoints: Number of participants with immediate adverse events at 30 minutes, Number of participants with solicited injection site and systemic reactions at 7 days and 6 more. Started Feb 2020; status: terminated.
02
Drugs
HSV-529G103
03
Conditions
genital herpes
Beyond the preview
Go deeper on NCT04222985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04222985.